anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To prepare toilet soap containing Chinese medicine which eliminates chloasma and ephelis, prevents roughening of the skin, and is less liable to bring about cracking after drying, by adding ginseng extract, root extract of orchid, bone oil, honey, and seed oil of peach to a soap material. CONSTITUTION:A toilet soap containing Chinese medicine comprises a soap material and, added thereto, ginseng extract, root extract of orchid, bone oil, honey, and seed oil of peach. The ginseng serves to rejuvenate cells through promotion of metabolism of the body, thereby gradually removing chloasma and ephelis. The peach seed oil not only promotes absorption of nutrients through the skin but also renders the skin smooth, so that the skin becomes smooth to the touch. The root extract of orchid protect the surface of the skin. The honey is a nutrient for the skin, protects the skin, reduces an irritating action of the soap per se, and imparts a viscosity to generated foams. The bone oil enhances the bonding force of the soap per se, which make the soap less liable to bring about cracking even when the soap is allowed to stand for a long period of time for drying.
Participants (i.e., 9 elite weightlifters) performed-as part of their habitual training program from 08h:00 to 09h:45- two training sessions using respectively, PLA and POMj supplementations (500ml), with a recovery period of 48 h in between. Upon arrival for their first test session, each participant's body mass and height were recorded. Moreover, before and after each tested training session, oral temperature was recorded with a calibrated digital clinical thermometer (Omron, Paris, France; accuracy: 0.05°C) inserted sublingually for at least 3 min with the subjects in a seated resting position for at least 15 min. Also, before and after each training session, fasting blood samples (blood sample 2, 3, 4 and 5, Figure1) were collected and heart rate (HR) and systolic arterial pressure (SAP) were recorded using a heart rate monitor and a manual sphygmomanometer. Additionally, to assess the recovery kinetic of the biological parameters, blood sample, temperature, HR and SAP were collected at resting state (i.e., after 10 days of recovery, blood sample 6) and immediately (3min) after the training session which proceed the PLA session (blood sample 1). Given that values of markers of muscle damage remain raised for at least 7 days following intensive weightlifting exercises, a recovery period of 10 days was chosen to evaluate the biological resting state. Additionally, given that (i) using randomized order in this study will results in consuming POMj then PLA supplementations (after 48h) for some participant and (ii) the delayed effect of POMj (which we expect) could alter the results of PLA supplementation, in the present study investigators choose to avoid randomized order and to evaluate the PLA at first then the POMj effect using all the participant together. Supplements (1500ml) of placebo (PLA) or pomegrenate juice (POMj) were taken three times daily in the 48h which proceed the first and the second tested training sessions respectively (i.e. 250ml × 6 times with 8-h intervals between it). Moreover, during these tested sessions, subject consumed an additional 500ml of PLA and 500ml of POMj, respectively. The tested quantity of the natural POMj were prepared from a fresh pomegranate fruit 48h before the beginning of the experimentation and were shipped frozen and stored at -4°C. No additional chemical products were added to the natural POMj. Each 500-mL of the tested POMj contained 2.56g of total polyphenol, 1.08g of ortho-diphenols, 292.59mg of flavonoids and 46.75mg of flavonols. Subjects were reminded verbally through phone communication to consume at the required times their supplements. Placebo juice consisted of an Pomegranate-flavored commercial drink contained water, citric acid, natural flavor and natural identical flavor (Pomegranate), sweeteners (aspartame × (0.3g/l), acesulfame K (0.16g/l)), stabilizers (Arabic gum) and lacked antioxidants, fruit and vegetable extracts or vitamins. Placebo juice contains no polyphenols.
Two-lung ventilation: tidal volume 8 ml/kg, PEEP of 5 cmH2O. One-lung ventilation: tidal volume 6 ml/kg, PEEP of 5 cmH2O. Recruitment maneuver will be applied during one-lung ventilation.
A Vapotherm® device (Vapotherm Inc., Stevensville, MD) for HHHFNC support was used. The airflow rate was set to 6-8 L/min for HHHFNC (heat: 37 °C). The HHHFNC support had been applied through the small bore cannula in the Vapotherm as an interface. The FiO2 was regulated to keep the oxygen-saturation value between 92% and 95%.
These studies include participation by human subjects using a 3-day inpatient CRU protocol at St. Mary's Hospital. Studies include formal measurement of blood and urinary markers of kidney function, BOLD MR and multidetector CT scanning. Forty-two non-diabetic patients between 40 and 80 years of any race or ethnicity will be recruited. All will have hypertension (defined as BP≥140/90 mmHg or ongoing antihypertensive drug therapy) but will have less than 180 mmHg to be included (with or without drug therapy). These subjects will be free of cardiovascular events within 3 months and will not have implanted electrical devices, such as a pacemaker or defibrillator. All patients will have identified large vessel renovascular disease (RVD) for Aims 1, 2 and 3. At least 10% of these subjects will be of African-American descent (self-identified) and recruited in collaboration with the University of Mississippi under the direction of Dr. Luis Juncos and the University of Alabama under the direction of Dr. David Calhoun. For completion of Aims 2 and 3, a three-day evaluation will be repeated between three and four months later, and ongoing safety and imaging studies will be performed up to 24 months after MSC administration. Participants in these protocols will undergo transvenous kidney biopsy under the direction of Drs. McKusick and Misra and their colleagues in Interventional Radiology. All subjects for these studies will complete the research plan at Mayo Clinic, Rochester, Minnesota.
Lumbar puncture is an invasive procedure potentially inducing pain and anxiety indicated in elderly patients for cognitive assessment. Indeed, the measure of amyloid biomarkers and tau in the cerebrospinal fluid is useful in the etiological diagnosis of cognitive disorders. With the ageing of the population and the increase incidence of cognitive disorders, this diagnostic procedure will be more and more frequent. Many studies have shown the efficiency of hypnosis during invasive procedure, especially in young children. The absence of side-effect is a major asset in elderly patients at high iatrogenic risk. It represents an interesting alternative to anxiolytic or sedative treatments. Nevertheless, its effectiveness in the elderly during lumbar puncture remains to be demonstrated. Investigators hypothesized that hypnosis may decrease pain and anxiety during lumbar puncture associated to setting comfort situation (relational care, music, transcutaneous anesthesia).
The medical treatment consisted of acetazolamide (0.5-4 g/day) and short-term mannitol (bolus of 0.25-1 g/kg body weight) for a duration of about 1 week or repeated lumbar punctures to reduce intracranial pressure (20 mL each), as well as analgesics for headaches. The initial dosage of acetazolamide was 0.5 g daily in two divided doses, followed by dosage increases of one tablet every week up to a maximum dosage of 4 g/day. The dosage escalation was stopped if the participant had papilledema grade \<1 in both eyes, unless the presence of other symptoms such as headache or tinnitus suggested that the dosage escalation should continue. The dosage for the participants who were unable to tolerate the study drug was decreased gradually to a minimum of one half tablet daily. In addition, the weight loss program included a low-calorie diet (≤425 kcal/day) with a target weight loss of approximately 5-10%.
New methods of treating silica wetcake during precipitated silica materials manufacturing are provided. Such methods permit a significant increase in high solids content processing while simultaneously reducing high viscosity of the resultant particles for transport facilitation. The resultant precipitated silica wetcake is treated with a borate-containing dispersant to impart the necessary low viscosity characteristics thereto. Such a dispersant accords not only such a viscosity result, but will not char or otherwise discolor the silica particles during evaporation of the liquids within the wetcake itself. Furthermore, such a dispersant, if left on the surfaces of such particles, will not deleteriously affect the abrasivity, fluoride compatibility, or other dentifrice properties of the precipitated silica materials themselves. Also encompassed within this invention are the resultant precipitated silica particles exhibiting borate residues and dentifrices including such materials.
PROBLEM TO BE SOLVED: To obtain the subject cleaning agent having excellent in frothing, free from slimy feeling of the skin in rinsing and giving cleaned skin free from springiness by compounding a higher fatty acid salt and extract of acerola fruit. SOLUTION: This cleaning agent contains (A) a higher fatty acid salt (preferably an 8-22C fatty acid salt such as sodium laurate) and (B) an extract of acerola fruit. The amounts of the components A and B in the total composition are preferably 5-30wt.% and 0.01-5wt.%, respectively. The component B can be produced e.g. by squeezing 10 kg of acerola fruit, concentrating the obtained fruit juice, removing the scum by filtration, adding 18kg of 30% aqueous solution of propylene glycol to 2kg of the filtrate, aging the mixture by leaving at rest in a cold place for 7-10 days and filtering the aged product. The composition may be further compounded with a surfactant commonly used in detergent, a humectant, an oil, a water-soluble polymer, a chelating agent, etc.
The present invention provides a system for the improved detection of ecstasy-class compounds in biological samples. New ecstasy-class analogs are provided for detection of such ecstasy-class drugs. These analogs are compounds, or salts thereof, of a 2-amino-methylenedioxyphenyl (MDP) derivative attached to Z, where Z is a moiety capable of bonding, either directly or indirectly, with an immunogenic carrier, a detectable label, or a solid capture vehicle. Such analogs may be used to construct immunogens, enzyme or enzyme-donor conjugates, and other conjugates. The immunogens reproducibly generate antibodies with an exquisite ability to distinguish various ecstasy-class drugs in biological samples from potentially interfering substances. The specific antibodies and the conjugates may be used to distinguish and measure various ecstasy-class compounds in biological samples, such as those obtained from an individual suspected of substance abuse. In another aspect, the invention includes certain reagents, reagent combinations, and kits for performing assay methods for ecstasy-class compounds in a biological sample.
In accordance with the present invention, there are provided methods for the treatment of cystic renal diseases, vascular infarction, catabolic and growth consequences of uremia and other related indications in mammals, employing members of a defined class of polycyclic compounds as the active agent. In accordance with another embodiment of the present invention, it has been discovered that these compounds are effective agents for the treatment of renal dysplasias and/or renal hypoplasias in mammals. In accordance with yet another embodiment of the present invention, it has been discovered that these compounds are effective agents for enhancing glomerular development in mammals. In accordance with still another embodiment of the present invention, it has been discovered that these compounds are effective agents for enhancing kidney development in mammals suffering from chronic organ injury. In accordance with a further embodiment of the present invention, it has been discovered that these compounds are effective agents for protecting kidneys from the ongoing toxicity of treatment with steroid hormones. In accordance with a still further embodiment of the present invention, it has been discovered that these compounds are effective agents for maintaining substantially normal growth in neonates, pre-pubescent and pubertal mammals exposed to high dose steroid hormone therapy and improves the poor growth associated with the catabolic effects of chronic disease or uremia in these mammals. In accordance with yet a further embodiment of the present invention, it has been discovered that these compounds prevent or treat organ vascular infarction in mammals.
Background and Objectives: The arthroscopic biceps rerouting (BR) technique was introduced as a novel technique for large-to-massive rotator cuff tears (LMRCTs). This method can restore shoulder stability, and its biomechanical effect was verified in a cadaver experiment. Recent reports have shown favorable clinical outcomes. This study aimed to compare the clinical outcomes of partial repair with those of the BR technique in LMRCTs. Materials and Methods: We included 72 patients who had undergone LMRCTs. Arthroscopic partial repair was performed in 31 patients (group I), while repair with the BR technique was performed in 41 patients (group II). Functional and imaging outcomes were evaluated and compared using a visual analog scale for pain, range of motion (ROM), American Shoulder and Elbow Surgeons (ASES) score, Constant score, and Korean Shoulder Score (KSS) before the surgery and at 3, 6, and 12 months after the surgery and at the last follow-up. Tendon integrity was investigated using magnetic resonance in all the patients at 12 months postoperative. Results: The mean follow-up period was 22.11 ± 10.47 months (range, 12-53 months). Forward flexion (p = 0.02) and external rotation at the side (p = 0.04) were significantly higher in group II than in group I on postoperative day (POD) 12 months. For internal rotation, group II showed significant improvement compared to group I on POD 3 months (p = 0.002) and at 6 months postoperative (p = 0.01). On POD 12 months, the ASES (p = 0.047) and KSS (p = 0.048) were better in group II. Significant improvements in pain and clinical scores were observed in both groups at the last follow-up. However, the two groups had no significant differences in pain, clinical scores, or ROM at the last follow-up. Retear of the repaired tendon was observed in nine patients in group I (29.03%) and eight in group II (19.51%, p = 0.35). Conclusions: Partial repair and repair using the BR technique effectively improved clinical and radiologic outcomes. The BR technique revealed early recovery of ROM and better clinical results than partial repair at one year postoperative. This could be a useful method in treating LMRCTs.
The invention relates to a method for producing ganoderma spore by breaking wall. The invention includes the following operation steps: ganoderma spore preparation, acid regulating, composite enzymatic hydrolysis, multigelation, filtering, spray drying and wall breaking of ganoderma spore. The acid regulating enzymatic hydrolysis step includes: in ganoderma spore rehydrated strong solution, citric acid is used for regulating pH to be 4.5, and polyphenol oxidase, laccase and cellulose are added by the ratios of 2000U, 1000U and 4000U per g of ganoderma spore respectively. Constant temperature stirring is carried out at 45 DEG C for 3h. In the trial-production process, 100ml sample solution is centrifuged every other 1h, and supernate is utilized to determine total protein content. Appropriate enzyme addition amount and action time are determined. After enzymolysis is completed, instant enzyme inactivation is carried out at 100 DEG C. The wall-broken rate of the method of the invention reaches 98.5%, active ingredients of extract are ensured to be more abundant and complete, and natural resource is effectively utilized to reduce cost, thus achieving the aims of improving yield by technology and creating benefit by technology.
PURPOSE: To enable the processing of a material like an anion exchange resin delivery system having physical characteristics of Bingham plastic by making the cross-sectional area of a channel and an extrusion port larger than that of the channel and extrusion port combined with other funnel at the places of first and second ends. CONSTITUTION: When a material is pushed into a die assembly 20, the blade 56 of a die block extending to a slot 36 separates the material into individual parts. As the material is continuously pushed into the die assembly 20 by a roll extruder 18, the separated material is pushed through the space of the die assembly 20 to be pushed into the funnel 58 of the die block 44. By this action, the material is extruded from the die block 44 through parts 48, 50a, 50b. The end ports 50a, 50b have a cross-sectional area larger than that of the port 48 linearly aligned between those ports. This special form provides the same dimension and shape to an edible anion exchange resin delivery system material having the characteristics of Bingham plastic after the extrusion through the respective ports 48, 50a, 50b.
The purpose of this study was to analyze the correlation between vaginal flora and immune function Type 1 helper T cells/Type 2 helper T cells imbalance in females having HPV infections at high risk within the female reproductive tract. We selected 150 female patients who visited our hospital for reproductive tract inflammation between March 2019 and March 2021. They were divided into high-risk HPV-positive and high-risk HPV-negative groups according to the results of the HPV tests. Vaginal flora composition, density, diversity, and Th1/Th2 immune cell cytokine expression were assessed, and their correlations were analyzed. Compared to the HPV-negative group at high risk, the HPV-positive group at high risk exhibited significantly higher rates of Lactobacillius abnormalities, Chlamydia trachomatis and Mycoplasma urealyticum positivity(P<0.05). However, no statistically significant differences in the rates of Neisseria gonorrhoeae, bacterial vaginosis, mould, and trichomonad positivity were observed in both groups (P>0.05). The high-risk HPV-positive group displayed significantly higher rates of abnormal vaginal flora density and diversity compared to the HPV-negative group at high risk (P < 0.05). Compared to the HPV-negative group at high risk, the HPV-positive group at high risk exhibited significantly lower expression levels of Th1, Th1/Th2, IFN-γ, and IL-2 and higher expression levels of Th2, IL-4, and IL-10(P<0.05). Among patients having HPV infections at high risk, those with abnormal vaginal flora had lower expression levels of Th1, Th1/Th2, IFN-γ, and IL-2 and higher expression levels of Th2, IL-4, and IL-10 compared to those with normal vaginal flora, all of which were statistically significant(P<0.05). Vaginal flora dysbiosis was correlated with Th1/Th2 imbalance (P<0.05). Women with high-risk HPV infections in the female reproductive tract exhibit abnormal vaginal flora and immune function Th1/Th2 imbalance, characterized by a shift from Th1 to Th2. Moreover, there is a close correlation between vaginal flora dysbiosis and immune function Th1/Th2 imbalance.
PURPOSE:To obtain the compound useful as a perfume by reaction of readily available or producible theta-cyclohomogeranial as starting material with a propanal alkylimine in the presence of a base followed by hydrolysis with an acid. CONSTITUTION:y-Cyclohomogeranial of formula 3 is reacted with a propanal alkylimine of formula 2 (R is 1-6C alkyl or alicyclic group) in the presence of a base in an organic solvent followed by hydrolysis in the presence of an acid to obtain the objective compound, 4-(6,6-dimethyl-2-methylenecyclohexyl)-2- methyl-2 butenal of formula 1. The compound of the formula 1 presents amberlike, woody, iononelike, irislike, fruity or floral scent. The other objective sustainable perfume composition contains this compound of the formula 1 as active ingredient. The above production method is an industrially advantageous one because the aimed compound can be obtained only in a single step. By this method, the objective compound can be easily synthesized in a high yield and purity.
BACKGROUND: Chronic Myeloid Leukemia (CML), accounting for 15-20% of adult leukemia cases, is marked by the Philadelphia chromosome, resulting from the t(9;22)(q34;q11) translocation. This leads to uncontrolled cell proliferation and survival. Imatinib therapy lowers BCR-ABL levels, influencing telomere-associated proteins and increasing telomerase accessibility, indirectly boosting its activity. This study investigates the effects of MST-312 and imatinib, both individually and combined, on a CML cell line.
METHODS: The K562 cells were subjected to different doses of MST-312 and imatinib, including four combination concentrations. Cell viability and metabolic activity were measured using trypan blue and MTT assays at 24-, 36-, and 48-h post-treatment. Flow cytometry (AnnexinV/PI) assessed cell apoptosis after 36 h of treatment with MST-312 and imatinib, both individually and in combination. The expression levels of Bax, Bcl-2, hTERT, P21, P53, and c-Myc were determined via qRT-PCR.
RESULTS: Both MST-312 and imatinib independently reduced cell viability in a dose- and time-dependent manner. Their combination further decreased cell viability compared to monotherapy. Treatment of K562 cells with MST-312 and imatinib for 36 h increased Bax expression and the Bax/Bcl-2 ratio while decreasing Bcl-2 expression. Combined treatment significantly reduced hTERT ansd P21 gene expression compared to imatinib alone.
CONCLUSIONS: The combination of MST-312 and imatinib shows potential as a CML therapy. However, further research and clinical trials are necessary to validate these findings and determine their clinical relevance.
Subjects will apply Restasis® to the target nails for 24 weeks. Additionally, there is a 12 week follow up period post the treatment period.
Totally six drone systems are setup to be deployed in suspected OHCA cases as a complement to EMS. This is a single-arm intervention evaluating referral of bystanders during 112-calls to retrieve drone delivered AEDs in suspected OHCA.
PURPOSE: To spray an active material at an extremely low speed in a practically pure form by discharging the effective and cosmetically active material such as an aromatic by electrostatic spraying. CONSTITUTION: A case 2 is provided with a power supply 12, a high-voltage generator 14, additional circuit mechanisms 16a, 16b, an action adjusting means 20, a storage unit 4, a material 6 to be sprayed, a discharging means 8, and an electric contact means 5, and the material 6 can be set to a high potential generated by a high voltage DC. The discharging means 8 is a wick made of a porous polymer, for example, and the material 6 passes through it and is raised to its tip 9 by a capillary action. Since the tip 9 has a high electric field, the material 6 can be sprayed from the tip 9 as a spray of electrified droplets. The electrified droplets search for a nearest earth object and discharge charges. The earth target becomes a part of the body, e.g. skin, and the effective and cosmetically active material 6 is preferably discharged on it in use.
Within the usual care, no one of the attendees in the room will have specific interaction with the child during this procedure, with the exception of normal/necessary interaction by the nurse and/or parent. Only minimal distraction is allowed. The child will sit down on the treatment table with the legs stretched out in front of him and the puncture-side arm in a 90-90 position next to the head or stretched out and lying down along the body, with the nurse at the puncture side and the parent at the other side standing next to him. The researcher is also present in the room, within the child's field of vision. At the end of the procedure, the nurse tells the child that he/she did very well.